Cargando…

Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer

The retinoblastoma tumor suppressor (RB) is a critical regulator of E2F-dependent transcription, controlling a multitude of protumorigenic networks including but not limited to cell-cycle control. Here, genome-wide assessment of E2F1 function after RB loss in isogenic models of prostate cancer revea...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandigo, Amy C., Shafi, Ayesha A., McCann, Jennifer J., Yuan, Wei, Laufer, Talya S., Bogdan, Denisa, Gallagher, Lewis, Dylgjeri, Emanuela, Semenova, Galina, Vasilevskaya, Irina A., Schiewer, Matthew J., McNair, Chris M., de Bono, Johann S., Knudsen, Karen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397633/
https://www.ncbi.nlm.nih.gov/pubmed/34625422
http://dx.doi.org/10.1158/0008-5472.CAN-21-1159
_version_ 1784772161048674304
author Mandigo, Amy C.
Shafi, Ayesha A.
McCann, Jennifer J.
Yuan, Wei
Laufer, Talya S.
Bogdan, Denisa
Gallagher, Lewis
Dylgjeri, Emanuela
Semenova, Galina
Vasilevskaya, Irina A.
Schiewer, Matthew J.
McNair, Chris M.
de Bono, Johann S.
Knudsen, Karen E.
author_facet Mandigo, Amy C.
Shafi, Ayesha A.
McCann, Jennifer J.
Yuan, Wei
Laufer, Talya S.
Bogdan, Denisa
Gallagher, Lewis
Dylgjeri, Emanuela
Semenova, Galina
Vasilevskaya, Irina A.
Schiewer, Matthew J.
McNair, Chris M.
de Bono, Johann S.
Knudsen, Karen E.
author_sort Mandigo, Amy C.
collection PubMed
description The retinoblastoma tumor suppressor (RB) is a critical regulator of E2F-dependent transcription, controlling a multitude of protumorigenic networks including but not limited to cell-cycle control. Here, genome-wide assessment of E2F1 function after RB loss in isogenic models of prostate cancer revealed unexpected repositioning and cooperation with oncogenic transcription factors, including the major driver of disease progression, the androgen receptor (AR). Further investigation revealed that observed AR/E2F1 cooperation elicited novel transcriptional networks that promote cancer phenotypes, especially as related to evasion of cell death. These observations were reflected in assessment of human disease, indicating the clinical relevance of the AR/E2F1 cooperome in prostate cancer. Together, these studies reveal new mechanisms by which RB loss induces cancer progression and highlight the importance of understanding the targets of E2F1 function. SIGNIFICANCE: This study identifies that RB loss in prostate cancer drives cooperation between AR and E2F1 as coregulators of transcription, which is linked to the progression of advanced disease.
format Online
Article
Text
id pubmed-9397633
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-93976332023-01-05 Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer Mandigo, Amy C. Shafi, Ayesha A. McCann, Jennifer J. Yuan, Wei Laufer, Talya S. Bogdan, Denisa Gallagher, Lewis Dylgjeri, Emanuela Semenova, Galina Vasilevskaya, Irina A. Schiewer, Matthew J. McNair, Chris M. de Bono, Johann S. Knudsen, Karen E. Cancer Res Molecular Cell Biology The retinoblastoma tumor suppressor (RB) is a critical regulator of E2F-dependent transcription, controlling a multitude of protumorigenic networks including but not limited to cell-cycle control. Here, genome-wide assessment of E2F1 function after RB loss in isogenic models of prostate cancer revealed unexpected repositioning and cooperation with oncogenic transcription factors, including the major driver of disease progression, the androgen receptor (AR). Further investigation revealed that observed AR/E2F1 cooperation elicited novel transcriptional networks that promote cancer phenotypes, especially as related to evasion of cell death. These observations were reflected in assessment of human disease, indicating the clinical relevance of the AR/E2F1 cooperome in prostate cancer. Together, these studies reveal new mechanisms by which RB loss induces cancer progression and highlight the importance of understanding the targets of E2F1 function. SIGNIFICANCE: This study identifies that RB loss in prostate cancer drives cooperation between AR and E2F1 as coregulators of transcription, which is linked to the progression of advanced disease. American Association for Cancer Research 2022-01-15 2021-10-08 /pmc/articles/PMC9397633/ /pubmed/34625422 http://dx.doi.org/10.1158/0008-5472.CAN-21-1159 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Molecular Cell Biology
Mandigo, Amy C.
Shafi, Ayesha A.
McCann, Jennifer J.
Yuan, Wei
Laufer, Talya S.
Bogdan, Denisa
Gallagher, Lewis
Dylgjeri, Emanuela
Semenova, Galina
Vasilevskaya, Irina A.
Schiewer, Matthew J.
McNair, Chris M.
de Bono, Johann S.
Knudsen, Karen E.
Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer
title Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer
title_full Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer
title_fullStr Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer
title_full_unstemmed Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer
title_short Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer
title_sort novel oncogenic transcription factor cooperation in rb-deficient cancer
topic Molecular Cell Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397633/
https://www.ncbi.nlm.nih.gov/pubmed/34625422
http://dx.doi.org/10.1158/0008-5472.CAN-21-1159
work_keys_str_mv AT mandigoamyc noveloncogenictranscriptionfactorcooperationinrbdeficientcancer
AT shafiayeshaa noveloncogenictranscriptionfactorcooperationinrbdeficientcancer
AT mccannjenniferj noveloncogenictranscriptionfactorcooperationinrbdeficientcancer
AT yuanwei noveloncogenictranscriptionfactorcooperationinrbdeficientcancer
AT laufertalyas noveloncogenictranscriptionfactorcooperationinrbdeficientcancer
AT bogdandenisa noveloncogenictranscriptionfactorcooperationinrbdeficientcancer
AT gallagherlewis noveloncogenictranscriptionfactorcooperationinrbdeficientcancer
AT dylgjeriemanuela noveloncogenictranscriptionfactorcooperationinrbdeficientcancer
AT semenovagalina noveloncogenictranscriptionfactorcooperationinrbdeficientcancer
AT vasilevskayairinaa noveloncogenictranscriptionfactorcooperationinrbdeficientcancer
AT schiewermatthewj noveloncogenictranscriptionfactorcooperationinrbdeficientcancer
AT mcnairchrism noveloncogenictranscriptionfactorcooperationinrbdeficientcancer
AT debonojohanns noveloncogenictranscriptionfactorcooperationinrbdeficientcancer
AT knudsenkarene noveloncogenictranscriptionfactorcooperationinrbdeficientcancer